News｜Cend Therapeutics

Cend Therapeutics to Participate in BIO Digital Conference June 8-12, 2020

May 5, 2020

LA JOLLA, CA, May 5, 2020 — Cend Therapeutics Inc. a clinical stage oncology biotech, today announced that the company will attend the BIO Digital Conference on June 8-12, 2020.

Harri Jarvelainen, Chief Operating Officer will host virtual one-on-one meetings throughout the conference. Please contact us to arrange a meeting.

Cend Therapeutics Selected as a Buzz of BIO 2020 Finalist

March 18, 2020

Cend Therapeutics Inc, a clinical-stage oncology company developing innovative therapies to overcome drug delivery barriers in solid tumors, today announced that it was selected as one of the finalists of Buzz of BIO International Convention.

The Buzz of BIO contest provides great visibility and an excellent opportunity for companies looking to make the connections needed to take their product to the next phase. The contest helps to identify companies based in the U.S. with groundbreaking technologies that have the overall potential to improve lives in difficult-to-treat conditions.

To vote, visit https://www.bio.org/events/bio-international-convention/buzz-bio-voting and select Cend Therapeutics in the “Pipelines of Promise” category (companies are listed alphabetically). Harri Jarvelainen, COO of Cend Therapeutics, is available for meetings during the conference.

Meet DrugCendR, Inc. at JP Morgan Healthcare Conference 2020 (January 12-16, San Francisco‎)

December 18, 2019

Harri Jarvelainen, COO of DrugCendR Inc., will meet investors and present data during the 37th JP Morgan Healthcare Conference, Jan 12-16, 2018, in San Francisco. Please contact us to arrange a one-on-one meeting.

For more information.

RECENT NEWS & RESOURCES

APR 7

INNOVATION Kyoto 2016 LPs Completes Strategic Investment in DrugCendR Inc.

(Kyoto, Japan / La Jolla, CA) – INNOVATION Kyoto 2016 Limited Liability Partnership (“KYOTO-iCAP 1st Fund”), and Kyoto University Innovation Capital Co., Ltd. (the general partner. Headquarters: Sakyo-ku, Kyoto City; CEO: Koji Murota; “Kyoto-iCAP”) and DrugCendR Inc. (Headquarters: La Jolla, CA, US; President and CEO: Erkki Ruoslahti; “DrugCendR”) today jointly announced that it has concluded a multimillion-dollar investment in DrugCendR, to accelerate the global development of DrugCendR’s breakthrough tumor penetrating technology.

“I am delighted to announce the completion of the strategic investment in DrugCendR Inc. We, Kyoto-iCAP, will continue to support the development of DrugCendR’s technologies in the long term.”said Koji Murota, CEO of Kyoto-iCAP.

“This investment into DrugCendR Inc. by Kyoto-iCAP and Kyoto University will allow us to complete our ongoing phase 1 clinical trial on the lead compound of the company” stated Dr. Erkki Ruoslahti, M.D., Ph.D., President and CEO of DrugCendR. “The strategic relationship with the fund and Kyoto University, a preeminent university in the world, will be important for us into the future. We will also collaborate with clinical researchers led by Dr. Yoshiharu Sakai, M.D., Ph.D., Professor of Surgery on clinical studies the university is uniquely equipped to perform. We hope to provide new treatment options for cancer patients in the US, Japan and elsewhere in the world.”

Concurrent with the investment, DrugCendR will initiate non-clinical and clinical research collaboration with Kyoto University. Professor Yoshiharu Sakai, M.D., Ph.D., Gastrointestinal Surgery, Department of Surgery, Kyoto University and Associate Professor Kazutaka Obama, M.D., Ph.D. will lead the collaboration for Kyoto University.

MAR 25

DrugCendR to Present Immuno-Oncology Data at the annual AACR meeting

DrugCendR Inc. COO Harri Jarvelainen will present a poster at the annual American Association for Cancer Research (AACR) meeting (March 29-April 4, 2019, Atlanta, GA). The poster is entitled “Co-administration of the iRGD tumor-penetrating peptide improves the tumor immunostimulatory effects of low-dose IL-2”.

FEB 9